IP Verse

J A Kemp competitive analysis

Explore patent oppositions filed by J A Kemp against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 27, 2026

Patent Number	Title	Applicant	Opposition Date
EP4358995	A Myostatin Pathway Inhibitor In Combination With A Glp-1 Pathway Activator For Use In Treating Metabolic Disorders	SCHOLAR ROCK	Aug 6, 2026
EP3749353	Nemolizumab In The Treatment Of Atopic Dermatitis With Moderate To Severe Excoriation	CHUGAI SEIYAKU KABUSHIKI KAISHA	Apr 30, 2026
EP4346839	Pharmaceutical Compositions For Clinical Nutrition	BAXTER	Dec 23, 2025
EP3369420	Compositions And Methods For Improving Mitochondrial Function And Treating Neurodegenerative Diseases And Cognitive Disorders	AMAZENTIS	Dec 11, 2025
EP3823594	Liquid Antibody Formulation	ICHNOS SCIENCES	Nov 5, 2025
EP4234033	Uses For And Article Of Manufacture Including Her2 Dimerization Inhibitor Pertuzumab	F HOFFMANN LA ROCHE	Oct 28, 2025
EP3509637	Methods Of Using A Bispecific Antibody That Recognizes Coagulation Factor Ix And/Or Activated Coagulation Factor Ix And Coagulation Factor X And/Or Activated Coagulation Factor X	CHUGAI SEIYAKU KABUSHIKI KAISHA	Aug 27, 2025
EP3305321	Therapeutic Agent And Therapeutic Method For Pulmonary Hypertension	KYOWA HAKKO KIRIN	Jul 16, 2025
EP3487881	Methods Of Treating New-Onset Plaque Type Psoriasis Using Il-17 Antagonists	NOVARTIS	May 21, 2025
EP3888674	Treatment Of Cancer Using Anti-Cd19 Chimeric Antigen Receptor	NOVARTIS	Jan 3, 2025

Discover the latest PTAB cases involving J A Kemp, highlighting their recent legal challenges and patent disputes.

IP litigation analysis comparing J A Kemp with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
J A KEMP	46	-	-	-